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Abstract
The AbsA1-AbsA2 two component signalling system of Streptomyces coelicolor has long
been known to exert a powerful negative influence on the production of the antibiotics acti-
norhodin, undecylprodiginine and the Calcium-Dependent Antibiotic (CDA). Here we report
the analysis of a ΔabsA2 deletion strain, which exhibits the classic precocious antibiotic
hyper-production phenotype, and its complementation by an N-terminal triple-FLAG-tagged
version of AbsA2. The complemented and non-complemented ΔabsA2 mutant strains were
used in large-scale microarray-based time-course experiments to investigate the effect of
deleting absA2 on gene expression and to identify the in vivo AbsA2 DNA-binding target sites
using ChIP-on chip. We show that in addition to binding to the promoter regions of redZ and
actII-orfIV AbsA2 binds to several previously unidentified sites within the cda biosynthetic
gene cluster within and/or upstream of SCO3215—SCO3216, SCO3217, SCO3229—
SCO3230, and SCO3226, and we relate the pattern of AbsA2 binding to the results of the
transcriptomic study and antibiotic phenotypic assays. Interestingly, dual ‘biphasic’ ChIP
peaks were observed with AbsA2 binding across the regulatory genes actII-orfIV and redZ
and the absA2 gene itself, while more conventional single promoter-proximal peaks were
seen at the CDA biosynthetic genes suggesting a different mechanism of regulation of the
former loci. Taken together the results shed light on the complex mechanism of regulation of
antibiotic biosynthesis in Streptomyces coelicolor and the important role of AbsA2 in control-
ling the expression of three antibiotic biosynthetic gene clusters.
Introduction
The bacteria of the genus Streptomyces are notable for their ability to undergo morphological
differentiation and for their ability to synthesize a wide variety of secondary metabolites. The
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model streptomycete, Streptomyces coelicolor A3(2), produces several antibiotics, including the
non-ribosomally synthesised lipopeptide Calcium Dependent Antibiotic, CDA [1], the blue
pigmented polyketide, actinorhodin (ACT) [2] and the red pigmented undecylprodiginines
(RED) [3]. The genes responsible for the biosynthesis of each of the antibiotics are located in
distinct clusters [2–4] each of which comprise a SARP (streptomycete antibiotic regulatory
protein) gene encoding a pathway specific activator protein i.e. cdaR [5], redZ [6], redD, [7]
and actII-orfIV, [8–9]. Induction of antibiotic biosynthesis is closely linked to morphological
differentiation and the transcription of genes involved in both processes are controlled by
complex regulatory networks in response to environmental and physiological stimuli [10]. The
absA locus was originally identified by isolating mutants unable to synthesize antibiotics but
unaffected in their morphological development [11]. Sequencing of this locus identified two
genes, absA1 and absA2 which comprise a two-component system, with AbsA1 possessing
similarity to other streptomycete antibiotic biosynthetic cluster associated histidine-kinase
sensor-transmitter proteins and AbsA2 displaying similarity to DNA-binding response regula-
tor proteins [12]. The location of absA1/2 within the CDA biosynthetic gene cluster was only
demonstrated after the determination of the S. coelicolor genome sequence [5, 13–14].
Sequencing of the original absA mutants by the Champness laboratory, together with sup-
pressor mutants [15], and introduction of a series of deletion and point mutations [16],
strongly indicated that the active, autophosphorylated form of AbsA1 was responsible for gen-
erating the repressive, phosphorylated form of AbsA2. Biochemical experiments investigating
the activity of AbsA1 have confirmed the results of the genetic studies and showed that AbsA1
is able to phosphorylate and dephosphorylate AbsA2 [17]. The effect of gene dosage on the
activity of AbsA1 & 2 was also investigated and the fact that the absA1/2 transcript was more
abundant in the original absA1 mutant C542 [11] which possesses two amino acid changes in
a region thought to be involved in aspartylphosphatase activity [15] and less abundant in the
absA2 mutant C570, in which the phosphorylated aspartate residue has been changed to a glu-
tamate residue [16], relative to the parent strain J1501, suggested that absA2 is positively auto-
regulated and that the autoregulatory form is phosphor-AbsA2 [16].
S1 nuclease transcript mapping indicated that absA1 and absA2 were expressed as a single
bi-cistronic leaderless transcript from the promoter upstream of absA1 (P1) [16]. However,
absA2 is also expressed from a second promoter (P2) located inside absA1 [18], which is is 4–7
times stronger than that of P1, based on transcript abundance and reporter assays, and the
expression of absA2 is consequently higher than that of absA1. Significantly, the relative abun-
dances of the two transcripts appear not to vary throughout growth, or with growth media
type [18]
Ryding et al., [19] investigated the effect on the expression of the genes of the cda cluster in
J1501 and its derivative mutant absA C542 and detected expression from the promoters
upstream of SCO3230 (cdaPSI), SCO3249 (acp), SCO3229 (hmaS) and SCO3215 (glmT) in
J1501 but not in the C542 mutant. Expression from the promoters upstream of SCO3225
(absA1) and SCO3224 (a putative CDA resistance gene), was detected in C542 but not in
J1501. Significantly, this study revealed little evidence for the regulation of cdaR by AbsA1/2
although more conclusive evidence was found for the AbsA1/2 mediated regulation of redZ
[19], and the involvement of the absA locus in regulating actII-orfIV and redD has also been
noted [20]. Gel retardation assays, using phosphorylated and non-phosphorylated tagged ver-
sions of AbsA2, to investigate its binding to the promoters of SCO3217 (cdaR), SCO3226,
(absA1/2) and SCO3230 (cdaPSI) were unable to show that either form of AbsA2 bound the
respective promoter regions, which suggested that in vivo AbsA2 may bind cooperatively with
another protein e.g. CdaR [17] or require a particular DNA topology. More recently ChIP
studies using anti-AbsA2 antibodies to pull-down AbsA2 complexes were conducted, however,
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the only genes whose promoters were found to be bound by AbsA2 were those of cdaR, redZ
and actII-orfIV [21].
The results of McKenzie & Nodwell, (2007) suggest AbsA2 plays a role as a “master” regula-
tor of antibiotic biosynthesis and regulates the SARPs for the cda, act and red gene clusters
[21]. The present large-scale, time-course transcriptomic experiment, conducted in parallel
with an in vivo AbsA2 ChIP-on-chip study, was conceived to more comprehensively examine
the role of AbsA2, particularly with respect to the CDA biosynthetic gene cluster where several
promoters have been previously shown to be AbsA2 dependent [19].
Materials and methods
Strains
The Streptomyces coelicolor strain used in this study was MT1110 [22] which is a prototrophic
SCP1−, SCP2− derivative of the wild-type strain 1147 [23]. The construction of the MT1110
ΔcdaR mutant is provided in [24] where the deletion of the EcoRI fragment (+442 to +1174
bp) is described. Plasmid maintenance was done in E. coli JM109 (endA1, recA1, gyrA96, thi-1,
hsdR17, (rk- mk+), mcrA, relA1, supE44 λ-, Δ(lac proB), [F’ traD36, proAB+, lacIq, Δ(lacZ)M15).
The E. coli strain ET12567 (F- dam-13::Tn9 dcm-6 hsdM hsdR recF143 zjj-202::Tn10 rspL136)
[25] was used for propagation of plasmid DNA free from dam, dcm and hsd methylation and
when containing the conjugative vector pUB307, was used in E. coli/S. coelicolor conjugations
[26].
Construction of a ΔabsA2 strain and absA2-complementing plasmid
An absA2 deletion mutant was constructed using homologous recombination to replace the
wild-type gene with a truncated version containing an internal deletion of 618 bp out of a total
of 669 bp. An XbaI site was substituted for the wild-type nucleotides between positions
3538686 and 3539309 [14], so introducing a termination codon into the truncated version of
absA2, which terminates translation after incorporation of three amino acids (MIL). A 1,757
bp fragment containing part of the absA2 N-terminal coding sequence and upstream region
was amplified by PCR using primers “absA2up forward” and “absA2up reverse” (Table 1) and
cloned into pKC1132 as an EcoRI-XbaI fragment to generate pAW3. A 1,503 bp fragment con-
taining the C-terminal coding sequence of absA2 and part of the downstream region was
amplified by PCR using primers “absA2down forward” and “absA2down reverse” (Table 1)
and cloned as an XbaI-HindIII fragment into pAW3 to generate pAW33. Plasmid DNA of
pAW33, obtained from ET12567, was used to transform MT1110 protoplasts [23] and primary
apramycin resistant transformants were selected. Following three rounds of non-selective
growth, Apramycin sensitive colonies were identified by replica plating and the presence of
Table 1. List of DNA sequences of named oligonucleotides used in the present study.
Primer Sequence 50 - 30
absA2up forward AGAATTCTCTTGTAGCGTGCTGGAATG
absA2up reverse AATCTAGAGAATCATCCGATCCTTCCCT
absA2down forward AATCTAGAAGGCGGGACTGGTGAAGGA
absA2down reverse AAAAAGCTTGCGGACACGATGGTGCTC
3xFUp ATGGACTACAAGGACCACGACGGCG
3226Down CCGGATCCCTAACGGTTGAGGTCGGCGTCCTTC
ΔabsA2_F2 CGTCCCGGCCGGCACGAC
ΔabsA2_R2 CCCGGCGCACCGGAATCG
https://doi.org/10.1371/journal.pone.0200673.t001
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the ΔabsA2 deletion was verified by PCR analysis of chromosomal DNA from the wild-type
and ΔabsA2 isolate (S2 Fig). Briefly, the absA genomic regions of MT1110 wild-type and the
ΔabsA2 putative deletion strain were PCR amplified from genomic DNA using primers
“ΔabsA2_F2” and “ΔabsA2_R2” (Table 1). The FailSafe PCR system (Epicentre) was employed
and Premix E yielded successful amplification of the targeted regions from both strains (S2
Fig). The verified mutant strain was designated MT1110 ΔabsA2.
For the construction of a ΔabsA2 complementing plasmid an N-terminally triple-FLAG-
tagged version of absA2 was synthesized de novo by GenScript and supplied cloned into the
EcoRV site of pUC57. The 773 bp insert (S1 Fig) comprised the absA2 coding sequence, fused
at the N-terminus to a sequence encoding a triple-FLAG tag (3xF), together with the absA1-
absA2 intergenic region and the absA2 ribosome binding site. This insert does not comprise
the P2 promoter [18]. The insert was sub-cloned as a BamHI–XbaI fragment into similarly
cut pMT3226 [23], so that absA2 was under the control of the tandem glycerol-inducible (gyl)
promoters. The resultant plasmid pMT3226::3xF-absA2 was used to transform ET12567
(pUB307). This construct, and the parent vector pMT3226 as a negative control, were intro-
duced into MT1110 ΔabsA2 by conjugation [26]. The presence of the 3xF tagged version of
absA2 was confirmed in Apramycin resistant ex-conjugants by PCR using primers “3xFUp”
and “3226Down”. The pigmented antibiotic phenotypes of the complemented mutant
(MT1110 ΔabsA2 (pMT3226::3xF-absA2)) and non-complemented mutant (MT1110 ΔabsA2
(pMT3226)) strains were determined visually following growth on solid media plates i.e. Man-
nitol-Soya agar [23] and Oxoid Nutrient Agar (ONA) (Oxoid), supplemented with 0.5% glyc-
erol, to induce expression from the gyl promoters.
Bacterial culture
Spores were produced from confluent lawns of Streptomyces coelicolor cultures grown on Man-
nitol-Soya agar [23] and were pre-germinated by incubating at 30˚C, with shaking (200 r.p.m)
in 2YT (with the addition of 30% sucrose) for eight hours. For the main chIP-transcriptomic
experiment duplicate cultures for both the complemented (MT1110 ΔabsA2 (pMT3226::3xF-
absA2)) and ΔabsA2 (MT1110 ΔabsA2 (pMT3226)) strains were set up in parallel. Pre-germi-
nated spores were used to inoculate two-litre siliconized spring flasks containing 500 ml of
modified YEME [23] to give an O.D.450 of 0.06. The modified YEME comprised 10% sucrose
instead of 34% and glucose was replaced by glycerol. Apramycin (50 μg/ml) and 0.01% Anti-
foam 204 (Sigma) were also added. The cultures were incubated at 30ºC, with shaking (200 r.p.
m) and growth was monitored by following the O.D.450. Samples were taken for transcrip-
tomic, ChIP-on-chip and pigmented antibiotic assays at 14, 18 and 35 h after inoculation.
Replicate small-scale cultures designed to illustrate the pigmented antibiotic phenotypes of
MT1110 ΔabsA2 (pMT3226::3xF-absA2) and ΔabsA2 (MT1110 ΔabsA2 (pMT3226)), which
are shown in S3 Fig (panels (B) & (D)), were set up as described above with the difference that
500 ml non-siliconized spring flasks were used containing 100 ml of modified YEME and sam-
ples were taken at 16, 22, 28 and 48 h after inoculation.
Culture sampling and antibiotic assays
For transcriptomic studies 10 ml samples of culture were harvested as described in [27]. For
ChIP-on-chip studies 108 ml of each culture was formaldehyde cross-linked and quenched as
described by Allenby et al. [28] and divided into three 42 ml portions before being pelleted
(4,000 r.p.m, 4˚C, 10 min), and the supernatants discarded. The pellets were each washed
twice in 20 ml of PBS and stored at -20˚C. For pigmented antibiotic assays 10 ml of whole cul-
ture was frozen at -20˚C.
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CDA bioassays were conducted according to the method of Chong et al., [13]. Actinorho-
din assays were conducted according to the method of Bystrykh et al., [29] modified as
described by Lewis et al., [27], whilst undecylprodiginine assays were conducted according to
the method of Tsao et al., [30], modified as described by Lewis et al., [27].
Nucleic acid isolation and ChIP-on-chip techniques
For this study a protocol, based on the standard protocol “Total RNA extraction by Tissue
Lyser”, described previously [31],was developed which allows the isolation of all RNA species,
including small RNAs. Following the passaging of the sample through the Qiagen RNeasy
gDNA eliminator column, the flow-through was mixed with an appropriate volume of ethanol
and used in the protocol “F.1. Total RNA Isolation Procedure” according to the Ambion “mir-
Vana miRNA Isolation Kit” instructions. The quality of the RNA obtained was assessed by
running a Bioanalyzer Prokaryote Total RNA Nano chip (Agilent) and only RNA having a
RNA Integrity Number of 6.5 or above was used in subsequent work. Protocols for S. coelicolor
MT1110 genomic DNA isolation and labelling (Cy5), together with the labelling of cDNA
(Cy3) were as previously described [28] and hybridizations were set up as before [32] using 2 x
105 K high-density IJISS Streptomyces whole genome microarrays [33]. The transcriptomic
microarray data are deposited with ArrayExpress (Accession Number:- E-MTAB-3528).
Protocols for the chromatin extraction and immunoprecipitation techniques for the ChIP-
on-chip experiment were as previously described [32] with the modifications that the antibody
used was the M2 mouse monoclonal anti-FLAG antibody from Sigma and the pull-down was
effected using Protein G magnetic beads (New England Biolabs). The DNA obtained was
labelled and hybridised to 2 x 105 K Streptomyces microarrays, as previously described by
Lewis et al., [33]. The antibody immunoprecipitated chromatin was co-hybridized directly
with mock “no antibody” immunoprecipitated chromatin i.e. the sample processed in the
same way as the antibody immunoprecipitated chromatin, but without use of the specific anti-
body. To compensate for any dye bias in the experiment replicate hybridisations were con-
ducted on different arrays with chromatin samples labelled in opposite Cy-dye orientations.
The ChIP-on-chip microarray data are deposited with ArrayExpress (Accession Number:-
E-MTAB-3527).
Microarray chIP data processing
Pre-processing. Microarray image files were scanned and imported into the Agilent Feature
Extraction software (v9.1) for image analysis and resulting files were processed in R. Log2 val-
ues were scale-normalized using the “normalizeMedianAbsValues” function in R Bioconduc-
tor package Limma [34–35]. Probes were filtered out based on Agilent feature flags QC
metrics [36]. In each time point, probes were excluded if they were flagged (in both channels)
in one or more samples in both strains or in more than two samples.
AbsA2 enrichment, clustering and regions of binding. Candidate probes for AbsA2
enrichment were defined as those for which their value in the complemented mutant (3xF)
sample is larger than their value in the non-complemented (ΔabsA2) mutant sample in both
replicates. Candidate probes with a fold-change (defined as the difference between the aver-
aged 3xF values and averaged ΔabsA2 values) larger than 1.0 standard deviation from the
mean fold-change across all candidate probes were defined as AbsA2-enriched probes. These
probes were then clustered based on their genomic position and 1 kb contiguous segments in
which at least two enriched probes were identified were considered to be ‘regions of AbsA2
binding’, and thus of interest. Lists of genes comprising such regions of binding are provided
in S4 Fig (14 h), S5 Fig (18 h) and S6 Fig (35 h) and the ChIP probe data is detailed in S3 Table.
Regulation of antibiotic biosynthesis by AbsA2
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Microarray expression data processing
As for the ChIP-on-chip data, the raw expression data Feature Extraction files were imported
into R for processing with Limma. No spatial effects were found, therefore the log2 values from
all arrays within the experiment were normalised by the ‘global median within array’, followed
by the ‘scale across array’ normalisation methods. Poor quality probes, as determined by the
Agilent software, were filtered from the data set. The representative expression signal for a
gene was calculated by averaging all good quality probes that target the annotated coding
region for that gene. Thus, for each time-point in each condition two values, one for each bio-
logical replicate, were obtained for every gene in the S. coelicolor genome. The processed quan-
titative microarray data is provided in S1 Table. The replicated gene data were analysed for
significant differential expression between the complemented and non-complemented strains
using Rank Product analysis via the web-tool RankProdIt [37–38] using a percentage false pos-
itive (pfp) cut-off value of 0.15.
Results and discussion
Antibiotic phenotypes of the complemented and non-complemented
ΔabsA2 strains
The deletion from S. coelicolor MT1110 of the majority of the absA2 coding sequence coupled
with the introduction of a termination codon was expected to confer the classic precocious
hyperproduction of antibiotic (pha) antibiotic phenotype on MT1110 with regard to CDA,
ACT and RED biosynthesis, [16]. The non-complemented mutant strain (MT1110 ΔabsA2
(pMT3226) over-expressed ACT and RED relative to the wild-type strain on a number of dif-
ferent solid media, whilst the complemented mutant (MT1110 ΔabsA2 (pMT3226::3xF-
absA2)) exhibited a hyper-repressed pigmented antibiotic phenotype (Fig 1(A)–1(C)). Addi-
tionally, it was confirmed that in small-scale liquid cultures in modified YEME medium that
the complemented mutant, MT1110 ΔabsA2 (pMT3226::3xF-absA2), exhibited a repressed
pigmented antibiotic phenotype relative to the non-complemented mutant ΔabsA2 (MT1110
ΔabsA2 (pMT3226)) (S3 Fig panels (B) and (D)). The repression of ACT and RED production
by introduction of the heterologously expressed version of absA2 demonstrates that the N-ter-
minally triple-flag tagged version of AbsA2 is capable of complementing the ΔabsA2 and is
likely to be a substrate for AbsA1 kinase activity, given that phosphorylated AbsA2 is known to
be the functional form of the protein, and it is presumably capable of binding to the actII-orfIV
and redZ promoters.
Surprisingly the CDA over-production phenotype, (Fig 1(D) and 1(E)) seen in MT1110
ΔabsA2 (pMT3226) was not reversed by introduction of the N-terminally triple-FLAG tagged
version of absA2. We will return to discuss this below.
The time points at which the liquid cultures were sampled were primarily chosen to investi-
gate AbsA2 binding rather than gene expression. Hence, we chose to sample at mid-exponen-
tial phase (14 h) i.e. before the onset of pigmented antibiotic production, when we would
predict AbsA2 would be bound to the known targets cdaR, redZ and actII-orfIV), at late expo-
nential phase (18 h) which correlated with the onset of RED biosynthesis (as determined by
visual inspection) when we might expect AbsA2 binding of actII-orfIV only and stationary
phase (35 h) when ACT biosynthesis had begun (as determined by visual inspection) when we
would predict AbsA2 binding of all three known targets would be abolished. This sampling
methodology meant that the cultures were sampled before full development of their pigmented
antibiotic phenotypes, as results of the pigmented antibiotic assays on the liquid cultures indi-
cate (S3 Fig panels (A) and (C)).
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Transcriptomic analysis of the complemented and non-complemented
ΔabsA2 strains
The results (S2 Table.) of the absA2 transcriptomic study indicated that, as expected from the
results of the antibiotic phenotypic assays, a large number of antibiotic biosynthetic genes
were significantly differentially expressed in the 3xFabsA2 strain relative to the ΔabsA2 strain.
At stationary phase (35 h) sixteen genes of the actinorhodin biosynthetic gene cluster are
up-regulated in the ΔabsA2 strain relative to the 3xFabsA strain (S1 and S2 Tables) which cor-
relates well with the results of the ACT assays in liquid culture, (S3 Fig) and the phenotypic
assays on solid media, (Fig 1(A)–1(C)).
Fig 1. Pigmented antibiotic and Calcium Dependent Antibiotic phenotypes of strains used in the study. MS agar
(A), ONA (B) and R5 (C) plates illustrating the ACT and RED phenotypes and CDA bioassay plates, plus Ca2+ (D) and
minus Ca2+ (E) illustrating the CDA production phenotypes of: (a) MT1110; (b) MT1110 ΔabsA2 (pMT3226); (c)
MT1110 ΔabsA2 (pMT3226::3xFabsA2); (d) MT1110 Δcda.
https://doi.org/10.1371/journal.pone.0200673.g001
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The fact that no genes of the red biosynthetic gene cluster are represented amongst the sig-
nificantly differentially expressed genes was expected given the similarity of the RED pheno-
types of both the 3xFabsA2 and ΔabsA2 strains in liquid culture, (S3 Fig (panel (A)). This may
be explained by the sampling of the cultures at a relatively early time-point before the full
development of the RED phenotypes which were observed in the small-scale cultures designed
to illustrate the pigmented antibiotic phenotypes of the strains (S3 Fig panel (B)).
The results of the CDA bioassay are consistent with the results of the transcriptomics exper-
iment which demonstrate that many genes of the cda cluster are well represented in the lists of
significantly differentially expressed genes, being up-regulated in the complemented mutant
relative to the non-complemented mutant. Three genes of the cda cluster are up-regulated in
the 3xFabsA2 strain relative to the ΔabsA2 strain at the mid exponential time-point (14 h),
whilst nineteen cda genes are up-regulated in the 3xFabsA2 strain relative to the ΔabsA2 strain
at the late-exponential phase time-point (18 h) (S1 Table). Consideration of these results must
of course exclude SCO3226 (absA2) whose differential expression was expected due to its dele-
tion from the ΔabsA2 strain, rather than due to bona fide changes in its expression.
When the results of the transcriptomic study are compared with the AbsA2 “network mod-
ule” of Castro-Melchor et al., [39] with the exceptions of SCO3220-3224 (cda genes) none of
these genes appear in the list of significantly differentially expressed genes.
The same study [39] also described a CdaR “network module”. However, these genes do
not correlate with the results presented herein, excepting SCO7717 which is up-regulated in
the complemented ΔabsA2 strain relative to the non-complemented ΔabsA2 strain at the 18 h
time-point. As cdaR is similarly up-regulated at this time-point this is consistent with CdaR
being a positive regulator of SCO7717.
ChIP-on-chip analysis of AbsA2 in the FLAG-tagged absA2 and ΔabsA2
strains
To investigate whether the significantly differentially expressed genes (S2 Table) were directly
regulated by AbsA2 we conducted ChIP-on-chip studies on samples taken at the same time-
points as those for the transcriptomic studies. The genes with background shading in S2 Table
are those which also feature in the ChIP-on-chip enriched probe cluster list. It is difficult to
interpret the majority of these in terms of the known function of AbsA2 i.e. regulation of anti-
biotic biosynthesis. Whilst we cannot exclude the possibility that AbsA2 does regulate these
genes, an in depth visual analysis of the chIP binding data, in combination with the expression
patterns, and knowledge of gene function, has been unable to establish meaningful correlations
between AbsA2 binding and gene expression/function for the majority of these genes. We
therefore confine further discussion/analysis of the results to known, validated AbsA2 targets
(i.e. cdaR, redZ and actII-orfIV) and to genes of the cda cluster, based on the results of a previ-
ous absA2 deletion study [19].
Although the transcriptomic results indicate AbsA2 exerts a strong effect on expression of
the cda genes it was unclear whether these effects were directly, or indirectly, mediated by
AbsA2, therefore, the results of the ChIP study relating to the cda cluster were of particular
interest. Indeed, the ChIP data indicated that AbsA2 does bind to several sites within the cda
cluster, binding to a region upstream of SCO3217 (cdaR), to the intergenic region of SCO3215
(glmT) and SCO3216 (ATPase), to the intergenic region between SCO3229 (hmaS) and
SCO3230 (cdaPSI), and lastly to another region within SCO3226 (absA2).
The AbsA2 ChIP peak which can most obviously be linked to a change in expression of a
particular gene at a certain time-point is the stationary phase peak seen in the SCO3215-
SCO3216 intergenic region which comprises two divergent promoters (Fig 2). This region
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does not contain ChIP peaks at the mid and late exponential phase time-points and the appear-
ance of the stationary phase peak correlates with a decrease in expression of SCO3215 in the
3xFabsA2 strain, relative to its level at the late exponential phase time-point. The expression
levels of the flanking genes remain similar in both strains at all time-points. The biological sig-
nificance of the stationary phase repression of SCO3215 (glmT), and presumably a consequen-
tial decrease in production of forms of CDA comprising methyl-glutamate, is unclear.
The relationship between AbsA2 binding and gene expression appears more complex at the
SCO3229 (hmaS)–SCO3230 (cdaPSI)—intergenic region. Although there are AbsA2 ChIP
peaks present at this locus at both the 14 and 18 h time-points in the 3xFabsA2 strain (Fig 3),
there is little difference in expression of the two genes between the 3xFabsA2 and ΔabsA2
strains at the 14 h time-point, although expression of both is markedly elevated in the
3xFabsA2 strain relative to the ΔabsA2 strain at the 18 h time-point. At the 35 h time-point no
ChIP peak is present and hmaS and cdaPSI are similarly expressed in both strains. This result
is intriguing since, given the wealth of previous genetic studies relating to AbsA2, it was
expected that an AbsA2 binding event would correlate with repression of transcription, as a
previous study reported that the C542 absA mutant repressed expression from both the
SCO3230 and SCO3229 promoters, relative to the parent strain, [19]. The lack of striking cor-
relation between AbsA2 binding events and expression levels suggests that in addition to
AbsA2 some other factor, or factors, is/are also involved in the regulation of cdaPSI and it is
very likely that CdaR plays an activatory role here.
The presence of a strong ChIP peak upstream of cdaR (SCO3217) (Fig 4) was expected
given the results of a previous ChIP study, [21]. AbsA2 peaks are observed at all three time-
points, (specific binding is most clearly demonstrated at the 14 and 18 h time-points) although
the effect of AbsA2 binding does not correlate with cdaR transcriptional activity, as expression
of cdaR is slightly repressed in the 3xFabsA2 strain relative to the ΔabsA2 strain at the 14 h
time-point, but then is more highly expressed at the 18 h and 35 h time-points. AbsA2 binding
per se may not be sufficient to regulate cdaR expression; for example, CdaR is known to be
autoregulatory (A. E. Hayes, Z. Hojati and CPS, unpublished data).
The situation observed here with regard to SCO3230 and SCO3217 is consistent with the
regulatory model proposed by Ryding et al., [19] who suggested “that the AbsA2 protein
directly regulates the cda biosynthetic promoters and in its negatively regulating form overrides
any positive regulation that may be exerted by cdaR” and they go on to suggest that “the nega-
tive regulatory effect of AbsA2 on CDA synthesis may serve to modulate cda expression in the
wild-type, perhaps in competition with cdaR putative activation”.
We believe that at the cdaR and cdaPSI promoters the triple-flag tagged version of AbsA2
present in the complemented mutant is able to bind DNA in a normal wild-type fashion giving
rise to the AbsA2 ChIP peaks observed. However, we suggest that unlike the wild-type AbsA2
the tagged version of the protein is unable to interact with, and repress, the transcription-acti-
vating effect of CdaR presumably due to the presence of the N-terminal triple-flag tag.
Fig 2. In vivo genomic distribution of 3xFAbsA2 in the region of glmT (SCO3215) and parallel measurement of
adjacent gene expression. The right hand y axis represents transcriptomic data (average log2 [cDNA/gDNA]) for
MT1110 ΔabsA2 (pMT3226) (orange line) and MT1110 ΔabsA2 (pMT3226::3xFabsA2) (blue line). The left hand y axis
represents chIP data (average log2 [complemented mutant/non-complemented mutant enrichment signal]) [i.e. the
Cy-dye balanced average MT1110 ΔabsA2 (pMT3226::3xFabsA) enrichment ratio relative to the same probe signal
from the same chromatin subjected to a mock no-Ab IP divided by the Cy-dye balanced average MT1110 ΔabsA2
(pMT3226) enrichment ratio relative to the same probe signal from the same chromatin subjected to a mock no-Ab
IP] (plotted as black columns). The x axis represents the genomic position of the microarray probes and the arrows
above represent genes and direction of transcription, with the main gene of interest being highlighted in red. Panels
(A), (B) & (C) refer to the 14 h (mid exponential phase), 18 h (late exponential phase) and 35 h (stationary phase) time-
points respectively.
https://doi.org/10.1371/journal.pone.0200673.g002
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Fig 3. In vivo genomic distribution of 3xFAbsA2 in the region of cdaPSI (SCO3230) and parallel measurement of
adjacent gene expression. See legend to Fig 2 for an explanation of the axes and colour coding. Panels (A), (B) & (C)
refer to the 14 h, 18 h and 35 h time-points, respectively.
https://doi.org/10.1371/journal.pone.0200673.g003
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Fig 4. In vivo genomic distribution of 3xFAbsA2 in the region of cdaR (SCO3217) and parallel measurement of
adjacent gene expression. See legend to Fig 2 for an explanation of the axes and colour coding. Panels (A), (B) & (C)
refer to the 14 h, 18 h and 35 h time-points respectively.
https://doi.org/10.1371/journal.pone.0200673.g004
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Therefore, although we see clear evidence of AbsA2 binding at these promoters we do not see
AbsA2 mediated transcriptional repression, as presumably CdaR is still active. This model sat-
isfactorily explains the non-complementation of the pha phenotype with regard to CDA by the
triple-flag tagged version of AbsA2 (Fig 1(D) and 1(E)). It is likely that the hyper-production
of CDA by the 3xFabsA2 strain, together with the enhanced expression of cdaR and cdaPSI in
the complemented mutant strain at the mid-exponential time-point (Fig 3 and Fig 4) is due to
the significant up-regulation of cdaR in the 3xFabsA2 strain at the mid-exponential phase
time-point, combined with the inability of the 3xF tagged version of AbsA2 to repress the acti-
vating effect of CdaR. The apparent AbsA2-mediated repression seen at the glmT promoter
(Fig 2) may be a genuine instance of AbsA2 directly mediating repression, or may merely
reflect a reduction in CdaR activity at this promoter during stationary phase.
The existence of a modified form of absA2 which possesses differential activities with regard
to CDA and ACT and RED biosynthesis is not unprecedented. When screening for mutations
able to suppress absA mutations Anderson et al., [15], discovered a mutant, C577S20, which
possessed a mutation encoding a V29A change in the N-terminus of AbsA2 and which pro-
duced ACT and RED but not CDA [15]. Although this situation is the opposite to that
described herein it does suggest that AbsA2 operates through two different repressive mecha-
nisms, one specific for CDA and the other for ACT and RED.
The final AbsA2 ChIP peak which targets the cda cluster is that which targets the internal
region of the absA2 gene (SCO3226) at the mid exponential phase time-point, (Fig 5). As the
native SCO3226 gene has been largely deleted in the complemented mutant the AbsA2 chIP
peaks are attributable to protein binding to the SCO3226 DNA in the heterologous 3xF-absA2
construct expressed from pMT3226 integrated into the ϕC31attP site; furthermore the
detected absA2 transcripts are derived via transcription from the adjacent tandem gylP1/P2
promoters in the expression vector.
It is tempting to interpret these binding events in terms of a negative autoregulatory mecha-
nism as AbsA2 has been shown to negatively regulate its own transcription, although an indi-
rect mechanism where AbsA2 regulates its own expression via an intermediary, e.g. CdaR,
could not be excluded [16]. We also note that the present study provides no evidence for
AbsA2 binding to the promoter upstream of absA1 (SCO3225) and that Sheeler et al., [17] also
did not observe binding of AbsA2 to the SCO3225 promoter region in vitro.
The most interesting aspect of the absA2 ChIP peak is that, in contrast to the ‘monophasic’
peak pattern observed upstream of glmT, cdaPSI and cdaR, the absA2 ChIP peak is located
internal to the gene and exhibits a curious asymmetrical, biphasic, form with a larger peak
closest to the start of the gene overlapping with or followed by a smaller peak near the end of
the gene.
In vivo binding of AbsA2 to the pathway specific activator-encoding genes for RED and
ACT, redZ and actII-orfIV. As expected from the literature [21], AbsA2 binds strongly to
redZ at the mid-exponential growth phase time-point, and although the AbsA2 ChIP peak per-
sists into the 18 h late exponential phase time-point in the 3xFabsA2 strain, here it does not
satisfy the ChIP enrichment scoring criteria (Fig 6). The redZ AbsA2 ChIP biphasic peak pat-
tern resembles that seen targeting absA2 (SCO3226), with one large peak upstream of the gene
and the second smaller peak within the gene. The fact that this unusual pattern is repeated at
both the 14 h and 18 h time-points suggests that this is a genuine phenomenon and not an
experimental artefact.
We note that although 3xFabsA2 only binds to and presumably represses redZ at the mid
exponential time-point there is little difference in RED biosynthesis between the 3xFabsA2
and the ΔabsA2 strains during the course of the experiment, although it is likely that differ-
ences in RED production would have become more obvious had the incubation of the culture
Regulation of antibiotic biosynthesis by AbsA2
PLOS ONE | https://doi.org/10.1371/journal.pone.0200673 April 10, 2019 13 / 23
been continued for a longer time as was done in the small-scale culture experiment (S3 Fig
panels (B) and (D)). This suggests that other transcription factors are involved in the regula-
tion of the genes of the red cluster. The delayed effect on RED biosynthesis caused by lack of
AbsA2 may therefore be due to long-lived, indirect, effects of AbsA2 exerting an influence on
RED through its effects on a regulatory network of transcription factors long after the initial
direct repression due to AbsA2 binding has been lifted.
A biphasic AbsA2 ChIP pattern is also observed in its binding to actII-orfIV (SCO5085)
where AbsA2 only binds in the 3xFabsA2 strain sample at the mid-exponential time-point (Fig
7). The lack of binding of AbsA2 at the later time-points correlates with a lifting of the repres-
sive effect of AbsA2 which is indicated by the increase in expression of actII-orfIV, observed
Fig 5. In vivo genomic distribution of 3xFAbsA2 in the region of absA2 (SCO3226) and parallel measurement of
adjacent gene expression. See legend to Fig 2 for an explanation of the axes and colour coding. The biphasic
3xFAbsA2 chIP peak is indicated by the pink dotted line. Panels (A) & (B) refer to the 14 h and 18 h time-points,
respectively.
https://doi.org/10.1371/journal.pone.0200673.g005
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markedly in the stationary phase sample. It is noteworthy that although AbsA2 only binds to
and represses actII-orfIV at the mid exponential time-point actinorhodin was not synthesized
by the 3xFabsA2 strain until the culture had reached stationary phase. The regulation of actinor-
hodin biosynthesis has been described as “amazingly complex” [10], with a large number of
transcription factors, including. AtrA [40], regulating ACT production. The effect on ACT bio-
synthesis observed here may therefore be due to long-lived, indirect, effects of AbsA2 exerting
an influence on ACT biosynthesis until stationary phase, through a regulatory network of tran-
scription factors long after the initial direct repression due to AbsA2 binding has been lifted.
A number of regulatory mechanisms could potentially explain the biphasic AbsA2 binding
patterns at absA2, redZ and actII-orfIV: AbsA2 binding to two sites independently; initially
binding one site and then sliding along the DNA to the other site; AbsA2 binding at one point
and then, following looping/coiling of the chromosome, contacting a second region of DNA at
a remote location. As it has been shown that AbsA2 is capable of binding to short probes in
gel-shift assays derived from the intergenic and 5’ terminus of actII-orfIV [21] it is unlikely
that the double peak represents an allosteric binding event where the binding of AbsA2 to the
upstream site is conditional on its occupancy of the downstream binding site.
It is tempting to interpret the differences in the mechanism of action of AbsA2 at (a) the
cdaR and cdaPSI promoters and (b) the redZ/actII-orfIV/absA2 genes in terms of the respective
morphologies of the ChIP peaks, where AbsA2 associated with monophasic ChIP peaks exerts
an indirect repressive effect on transcription by inhibiting activating transcription factors (e.g.
CdaR), whereas the biphasic pattern of AbsA2 binding is associated with direct repression by
AbsA2. Indeed, the fact that AbsA2 binding covers large portions of redZ, actII-orfIV and
absA2, would suggest that the genes are more tightly constrained by AbsA2 occupancy and
therefore less accessible to other transcription factors, than those with a single binding site.
We also note that the differences in AbsA2 ChIP peak form at the redZ, actII-orfIV and
cdaR promoters correlate with the fact that AbsA2 has been shown to bind more weakly to the
cdaR promoter than to the redZ and actII-orfIV promoters [21]. Our observed differences of in
vivo AbsA2 binding patterns at the target loci also perhaps explain why previous investigators
[21] have been unable to identify an AbsA2 consensus binding sequence and, despite our
more detailed knowledge of the AbsA2 target sites, we have also been unable to identify con-
sensus binding motifs using neither monophasic peak bound sequences nor biphasic peak
bound sequences, nor a combined dataset. A possible explanation for this apparent lack of
sequence specificity is that the binding of AbsA2 is dependent on factors other than the precise
sequence of the target DNA i.e. in the case of redZ and actII-orfIV the double-peak binding
pattern may be due to the effect of at least two widely spaced binding motifs, and possibly
long-range DNA topological factors which influence DNA coiling/looping. In the case of the
cda genes the presence/absence of binding DNA proteins (e.g. CdaR) may determine where
AbsA2 binds. Indeed, it has been suggested previously that AbsA2 binding is dependent on the
presence of CdaR [17].
The similarity of the absA2 and the redZ and actII-orfIV AbsA2 ChIP peaks also suggests an
interesting hypothesis as to how AbsA2 acquired the status of “master regulator” of antibiotic
synthesis. It is possible that initially AbsA2 was merely a ‘pathway specific’ regulator of the cda
biosynthetic gene cluster, in which it is located. However, due to the similarity in sequences of
the absA2, redZ and actII-orfIV genes when, through horizontal gene transfer, the biosynthetic
Fig 6. In vivo genomic distribution of 3xFAbsA2 in the region of redZ (SCO5881) and parallel measurement of
adjacent gene expression. See legend to Fig 2 for an explanation of the axes and colour coding. The biphasic
3xFAbsA2 chIP peak is indicated by the pink dotted line. Panels (A), (B) & (C) refer to the 14 h, 18 h and 35 h time-
points, respectively.
https://doi.org/10.1371/journal.pone.0200673.g006
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Fig 7. In vivo genomic distribution of 3xFAbsA2 in the region of actII orfIV (SCO5085) and parallel measurement
of adjacent gene expression. See legend to Fig 2 for an explanation of the axes and colour coding. The biphasic
Regulation of antibiotic biosynthesis by AbsA2
PLOS ONE | https://doi.org/10.1371/journal.pone.0200673 April 10, 2019 17 / 23
gene clusters were brought together in S. coelicolor, AbsA2 was able to bind the SARP genes of
the ACT and RED clusters and so extend its control over their gene clusters, in addition to the
cda cluster. This hypothesis is consistent with the fact that within the cda cluster AbsA2 oper-
ates as an integral part of a regulatory system in conjunction with the activator, CdaR, whilst
due to it being a recently acquired regulator of redZ and actII-orfIV it acts independently at
these loci, reflecting its recent integration into the endogenous transcription factor network.
3xFAbsA2 chIP peak is indicated by the pink dotted line. Panels (A), (B) & (C) refer to the 14 h, 18 h and 35 h time-
points, respectively.
https://doi.org/10.1371/journal.pone.0200673.g007
Fig 8. Summary of main findings from chIP analysis of AbsA2 binding. Schematic diagram illustrating the in vivo pattern of binding of 3xFabsA2
to selected genes from antibiotic biosynthetic gene clusters known, or predicted, to be bound by AbsA2. References providing evidence of AbsA2
binding are indicated alongside those chIP peaks they provide supporting evidence for. ‘Biphasic’ chIP peaks are shown in purple whilst ‘monophasic’
chIP peaks are shown in blue.
https://doi.org/10.1371/journal.pone.0200673.g008
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Conclusions
The present study used the powerful tool of high-density microarrays to investigate the regula-
tion of antibiotic production in Streptomyces coelicolor by the transcriptional regulator AbsA2.
Despite myriad genetic and molecular biological studies of this transcription factor the present
study represents the first attempt to integrate a transcriptomic study with chIP-on-chip tech-
nology to explore in vivo interactions of AbsA2 with the genome. The results (summarised in
Fig 8) indicate that AbsA2 binds to several loci within the cda cluster (SCO3215, SCO3217, and
SCO3230) and suggest that it exerts a repressive influence on transcription through negatively
regulating CdaR activity. Additionally, we show that AbsA2 also binds to its own gene
(SCO3226), providing evidence for an autoregulatory mechanism, and to the SARP genes of
the act (actII-orfIV) and red (redZ) clusters; differences between the patterns of the AbsA2
ChIP peaks at these genes and those within the cda cluster suggest that AbsA2 represses tran-
scription of these regulatory genes directly and raises the intriguing possibility that AbsA2 dis-
plays two different mechanisms of binding DNA and of mediating repression.
The results of this study go some way towards explaining and illuminating aspects of previ-
ous genetic and molecular studies of AbsA2. They also raise new questions as to the precise
mode of action of AbsA2 and it is hoped that these genome-wide results will serve to inform
and stimulate future work into this fascinating transcription factor.
Supporting information
S1 Fig. DNA sequence of the N-terminally triple flag tagged absA2 and upstream flanking
region. The green sequences represent restriction enzyme cut sites incorporated into the ter-
mini for ease of cloning. The black sequence represents the absA1- absA2 intergenic region,
the red sequence represents the DNA which encodes the triple-flag tag and the blue sequence
represents the absA2 coding sequence.
(PDF)
S2 Fig. PCR-based verification of the construction of the ΔabsA2 mutant. Upper panel:
Schematic diagram illustrating the absA genomic region and the location of the absA2 dele-
tion. The locations of the PCR primer target sequences and sizes of the MT1110 wild-type
PCR product (1,086 bp) and the ΔabsA2 PCR product (460 bp) are shown. Lower panel: Aga-
rose gel photograph illustrating PCR products of the expected sizes generated from MT1110
wild-type and the ΔabsA2 strain.
(PDF)
S3 Fig. Pigmented antibiotic production in liquid medium by the ΔabsA2 mutant and the
complemented strain. Actinorhodin (ACT) and undecylprodiginine (RED) assays from repli-
cate cultures of strains of MT1110 ΔabsA2 (pMT3226) and MT1110 ΔabsA2
(pMT3226::3xFabsA2) used in the main chIP/transcriptomic experiment: panels (A) & (C)
and from the independent small-scale pigmented antibiotic production experiment: panels (B)
& (D).
(PDF)
S4 Fig. Clustering results from the AbsA2 chIP study. List of genes (and clusters of genes)
identified at the 14 h time-point as containing two or more enriched microarray probes within
1 kb contiguous segmentsin MT1110 ΔabsA2 (pMT3226::3xFabsA2) relative to equivalent
probe data from MT1110 ΔabsA2 (pMT3226).
(TXT)
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S5 Fig. Clustering results from the AbsA2 chIP study. List of genes (and clusters of genes)
identified at the 18 h time-point as containing two or more enriched microarray probes within
1 kb contiguous segments in MT1110 ΔabsA2 (pMT3226::3xFabsA2) relative to equivalent
probe data from MT1110 ΔabsA2 (pMT3226).
(TXT)
S6 Fig. Clustering results from the AbsA2 chIP study. List of genes (and clusters of genes)
identified at the 35 h time-point as containing two or more enriched microarray probes within
1 kb contiguous segments in MT1110 ΔabsA2 (pMT3226::3xFabsA2) relative to probe data
from MT1110 ΔabsA2 (pMT3226).
(TXT)
S1 Table. Normalised gene expression microarray data used for the Rank Product analysis.
The probe signals from for each coding sequence were averaged; data in all columns is in log2
format. In the column headings “3xF” is used as an alternative to “MT1110 ΔabsA2
(pMT3226::3xFabsA2)” and “pMT” is used as an alternative to MT1110 ΔabsA2 (pMT3226)”.
Genes considered to be activated or repressed by AbsA2 are highlighted in green and red,
respectively (pfp < 0.15 from Rank Product analysis).
(XLS)
S2 Table. Summary of results of the transcriptomic and chIP studies. List of genes which
are significantly differentially expressed between MT1110 ΔabsA2 (pMT3226) and MT1110
ΔabsA2 (pMT3226::3xFabsA2) at the 14 h, 18 h and 35 h time-points (Rank Product pfp
<0.15). Genes in red are repressed in MT1110 ΔabsA2 (pMT3226::3xFabsA2) relative to
MT1110 ΔabsA2 (pMT3226). Genes highlighted in green are activated in MT1110 ΔabsA2
(pMT3226::3xFabsA2) relative to MT1110 ΔabsA2 (pMT3226). Genes which possess clusters
of ChIP-enriched microarray probes in MT1110 ΔabsA2 (pMT3226::3xFabsA2) relative to
MT1110 ΔabsA2 (pMT3226) are highlighted by green/red background shading; the method
used for clustering and scoring these clusters or ‘regions of interest’ is detailed in Materials
and Methods. Genes of the act biosynthetic gene cluster are highlighted by red borders and
genes of the cda biosynthetic gene cluster are highlighted by green borders.
(PDF)
S3 Table. AbsA2 chIP microarray data used in probe clustering analysis to identify
AbsA2-binding regions of interest. All candidate AbsA2-binding probes are listed and the
clustered probes used to identify regions of interest are included within this comprehensive
list. The criteria for scoring candidate probes are detailed in Materials and Methods. The three
separate sheets in the Excel spreadsheet list the AbsA2-enriched probes identified at each of
the respective three time points of 14 h, 18 h and 35 h. The Cy3 and Cy5 dyes were swapped
for the two biological replicates of each strain and the probe data was averaged; all data is pre-
sented in log2 format. The method used for identifying clusters of probes, designated ‘regions
of interest’ (listed in S4–S6 Figs) is detailed in Materials and Methods. Key: WT, MT1110
ΔabsA2 (pMT3226::3xFabsA2); MT, MT1110 ΔabsA2 (pMT3226); Fold_change = Average
(log 2 (WT)) − Average (log 2 (MT)).
(XLSX)
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